You are here: Industry Insights > Breast Cancer

News List

FDA expands approved use of metastatic breast cancer treatment to include male patients worldpharmanews
April 08, 2019
The U.S. Food and Drug Administration (FDA) today is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies...
Emcure launches generic Eribulin for treatment of metastatic breast cancer expressbpd
April 04, 2019
The drug will be available in India at approximately 40 per cent cost of the innovator brand
Roche’s ipatasertib combo shows early promise in triple-negative breast cancer pharmatimes
April 04, 2019
Roche has announced results from a Phase Ib trial assessing its AKT-inhibitor ipatasertib, Tecentriq (atezolizumab) and chemotherapy in triple-negative breast cancer (TNBC), showing a 73% overall response rate irrespective of PD-L1 status.
Long-term data shows promise in breast cancer biosimilar pharmatimes
April 03, 2019
The a three-year follow-up study comparing biosimilar Ontruzant (trastuzumab) to a reference version - Herceptin - has found that the drug shows comparable overall survival and cardiac safety in early or locally advanced HER2-positive breast cancer.
NICE nod for breast cancer delay drug pharmatimes
April 02, 2019
The National Institute for Health and Care Excellence (NICE) has recommended Eli Lilly’s Verzenio (abemaciclib) when given with Faslodex (fulvestrant), to be available for NHS use within the Cancer Drugs Fund (CDF).
Hematogenix introduces the FDA-approved immuno-oncological diagnostic adjunctive diagnostic test for triple-negative breast cancer pharmafocusasia
March 14, 2019
Hematogenix®, a global leader in integrated pathology services for drug development and immuno-oncological testing, today announced the introduction of the companion diagnostic test for TECENTRIQ®.
Roche’s Tecentriq notches win in breast cancer with US approval expressbpd
March 14, 2019
The FDA’s OK was based on a trial that showed the drug cocktail helped stave off the disease’s advance by a median 7.4 months, compared to 4.8 months with chemotherapy
Hematogenix Launches FDA Approved Companion Diagnostic Immuno-oncology Test for Triple-Negative Breast Cancer en-cphi.cn
March 13, 2019
Hematogenix® announced the launch of the companion diagnostic test for the drug TECENTRIQ®. On March 8, 2019.
Roche gets first checkpoint inhibitor OK in breast cancer pharmaphorum
March 12, 2019
Roche’s Tecentriq was the third PD-1/PD-L1 inhibitor to reach the market but is the first in class to be approved for any form of breast cancer
Roche's I-O drug Tecentriq picks up key first-in-class breast cancer nod! fiercepharma
March 12, 2019
In a first for the immuno-oncology field, Roche’s Tecentriq has a big new approval in breast cancer.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 26 27 Next page